Edition:
India

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

92.96EUR
3:36pm IST
Change (% chg)

€0.70 (+0.76%)
Prev Close
€92.26
Open
€92.50
Day's High
€94.36
Day's Low
€92.26
Volume
252,855
Avg. Vol
392,878
52-wk High
€94.36
52-wk Low
€59.13

Select another date:

Mon, Jan 8 2018

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

BRIEF-Galapagos Reports Preliminary Topline Results In Osteoarthritis Study

* REPORTED ON SUNDAY, POSITIVE PRELIMINARY TOPLINE RESULTS WITH A PHASE 1B STUDY IN OSTEOARTHRITIS (OA) PATIENTS IN THE UNITED STATES

BRIEF-Galapagos Exercises Co-Promotion Option For Filgotinib

* SAID ON THURSDAY IT WILL OPT-IN ON CO-PROMOTION OF FILGOTINIB WITH COLLABORATION PARTNER GILEAD SCIENCES IN EIGHT EUROPEAN COUNTRIES, SHOULD FILGOTINIB BE APPROVED FOR COMMERCIAL SALE

BRIEF-Galapagos To Enter NASDAQ Biotech Index Effective Dec 18‍​

* TO ENTER NASDAQ BIOTECH INDEX EFFECTIVE DEC 18‍​ Source text: http://bit.ly/2jM5AGV Further company coverage: (Gdynia Newsroom)

BRIEF-Galapagos NV ‍announces share capital increase arising from warrant exercises​

* ‍Announces a share capital increase arising from warrant exercises​

BRIEF-Galapagos NV reports Q3 loss of ‍1.75​ euro per share

* Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​

BRIEF-Galapagos & Morphosys announce Phase 1 results with joint investigational antibody program MOR106

* Co, Morphosys report first promising signs of clinical activity in phase 1 study with IL-17C antibody MOR106 in Atopic Dermatitis patients

BRIEF-Galapagos says GLPG1690 halts disease progression in IPF patients in mid-stage trial

* GLPG1690 halts disease progression in IPF patients in Flora phase 2A trial

BRIEF-Galapagos H1 revenues up at EUR 73.0 mln

* ANNOUNCED ON THURSDAY H1 REVENUES EUR 73.0 MLN VS EUR 48.8 MLN YEAR AGO

BRIEF-Servier announces it has exercised option to develop osteoarthritis molecule from Galapagos

* SERVIER ANNOUNCES IT HAS EXERCISED OPTION TO DEVELOP NOVEL OSTEOARTHRITIS MOLECULE GLPG1972/S201086 FROM GALAPAGOS NV, OBTAINING GLOBAL COMMERCIAL RIGHTS OUTSIDE THE U.S.

Select another date: